


I hereby certify that this correspondence is being  
electronically filed in the United States Patent  
and Trademark Office on March 9, 2007.



Frank C. Eisenschenk, Ph.D., Patent Attorney

AMENDMENT UNDER 37 CFR  
§1.825(a) THROUGH (c)  
Patent Application  
Docket No. ARS-124  
Serial No. 10/573,625

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Amanda Proudfoot, Jeffrey Shaw, Zoe Johnson  
Serial No. : 10/573,625  
Filed : March 28, 2006  
Conf. No. : 9024  
For : Therapeutic Uses of Chemokine Variants

Mail Stop PCT  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313

AMENDMENT UNDER 37 CFR §1.825(a) THROUGH (c)

Sir:

In response to the Notification of Missing Requirements Under 35 U.S.C. 371 in the United States Designated/Elected Office (DO/EO/US) received in the above-identified patent application, please amend the subject application as follows, in order to comply with the requirements of 37 CFR §§1.821-1.825: